Trials / Active Not Recruiting
Active Not RecruitingNCT05756972
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of PM8002(Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With EGFR-mutant Advanced Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Biotheus Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II study to evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment.
Detailed description
This study is a phase II, single-arm study, 64 participants were enrolled as of 6 Feb 2024, and recruitment was completed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PM8002 | IV infusion |
| DRUG | Carboplatin | IV infusion |
| DRUG | Pemetrexed | IV infusion |
Timeline
- Start date
- 2023-06-26
- Primary completion
- 2024-09-13
- Completion
- 2025-12-01
- First posted
- 2023-03-07
- Last updated
- 2025-04-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05756972. Inclusion in this directory is not an endorsement.